Altimmune Bolsters Cash Position with $225M Offering, Eyes Phase 3 Trial Launch
Event summary
- Altimmune raised $225M in April 2026 via public offering, boosting cash position to $535M.
- PERFORMA Phase 3 MASH trial initiation planned for second half of 2026.
- Topline data from RECLAIM Phase 2 AUD trial expected in Q3 2026.
- RESTORE Phase 2 ALD trial enrollment completion anticipated in Q3 2026.
- 48-week IMPACT data in MASH to be presented at EASL Congress 2026.
The big picture
Altimmune's recent financing strengthens its balance sheet, providing a robust runway for its clinical programs. The strategic focus on MASH, AUD, and ALD positions the company in high-growth therapeutic areas, though it faces intense competition and regulatory scrutiny. The upcoming data readouts and trial initiations will be critical in validating its dual-action therapy approach.
What we're watching
- Trial Execution
- The pace at which Altimmune initiates the PERFORMA Phase 3 trial will signal its operational readiness.
- Data Impact
- How the 48-week IMPACT data presentation at EASL influences investor sentiment.
- Market Positioning
- Whether Altimmune can sustain its momentum in the competitive MASH, AUD, and ALD treatment landscape.